BEAT - BioTelemetry, Inc.
| Previous Close | 54.56 |
| Open | 54.49 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 51.77 - 54.82 |
| 52 Week Range | 37.07 - 76.25 |
| Volume | 289,691 |
| Avg. Volume | 233,660 |
| Market Cap | 1.772B |
| Beta (5Y Monthly) | 1.38 |
| PE Ratio (TTM) | 48.72 |
| EPS (TTM) | 1.07 |
| Earnings Date | Feb 25, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.83 |
- Zacks
Earnings Preview: BioTelemetry (BEAT) Q4 Earnings Expected to Decline
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
BioTelemetry, Inc. to Release Fourth Quarter 2019 Earnings Results on February 26, 2020
MALVERN, Pa., Feb. 18, 2020 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its fourth quarter 2019 earnings on Wednesday, February 26 at 4:00 PM Eastern Time. The.
- Investor's Business Daily
Why You Should Keep An Eye On These 5 Leading Health Care Stocks
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
- Simply Wall St.
Should You Worry About BioTelemetry, Inc.'s (NASDAQ:BEAT) CEO Salary Level?
Joe Capper became the CEO of BioTelemetry, Inc. (NASDAQ:BEAT) in 2010. This analysis aims first to contrast CEO...
- Simply Wall St.
Don't Sell BioTelemetry, Inc. (NASDAQ:BEAT) Before You Read This
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- Simply Wall St.
Is BioTelemetry, Inc.'s (NASDAQ:BEAT) ROE Of 11% Impressive?
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
- Insider Monkey
Should You Buy BioTelemetry, Inc. (BEAT)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- Simply Wall St.
Does BioTelemetry, Inc. (NASDAQ:BEAT) Have A Particularly Volatile Share Price?
If you own shares in BioTelemetry, Inc. (NASDAQ:BEAT) then it's worth thinking about how it contributes to the...
- Thomson Reuters StreetEvents
Edited Transcript of BEAT earnings conference call or presentation 5-Nov-19 10:00pm GMT
Q3 2019 BioTelemetry Inc Earnings Call
- GuruFocus.com
Mario Gabelli Continues to Buy AbbVie, Axalta
9 High Conviction Stocks for GAMCO Investors Continue reading...
- Zacks
BioTelemetry (BEAT) Beats Q3 Earnings and Revenue Estimates
BioTelemetry (BEAT) delivered earnings and revenue surprises of 4.00% and 0.28%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioTelemetry, Inc. Reports Third Quarter 2019 Financial Results
Exceeds ExpectationsDelivers Double Digit Revenue Growth MALVERN, Pa., Nov. 05, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused.
- Simply Wall St.
If You Had Bought BioTelemetry (NASDAQ:BEAT) Shares Five Years Ago You'd Have Made 414%
For many, the main point of investing in the stock market is to achieve spectacular returns. While not every stock...
- GlobeNewswire
BioTelemetry, Inc. to Release Third Quarter 2019 Earnings Results on November 5, 2019
MALVERN, Pa., Oct. 29, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its third quarter 2019 earnings on Tuesday, November 5 at 4:00 PM Eastern Time. The BioTelemetry.
- Insider Monkey
Were Hedge Funds Right About Dumping BioTelemetry, Inc. (BEAT)?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
- Simply Wall St.
What Does BioTelemetry, Inc.'s (NASDAQ:BEAT) Share Price Indicate?
BioTelemetry, Inc. (NASDAQ:BEAT), which is in the healthcare business, and is based in United States, received a lot...
- Simply Wall St.
Is BioTelemetry, Inc.'s (NASDAQ:BEAT) Capital Allocation Ability Worth Your Time?
Today we are going to look at BioTelemetry, Inc. (NASDAQ:BEAT) to see whether it might be an attractive investment...
- GlobeNewswire
BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100 Fastest-Growing Companies list for 2019. The ranking is based on the combination of revenue growth, earnings growth and the three-year annualized total return. It applies to U.S. publicly traded companies.
- Simply Wall St.
BioTelemetry (NASDAQ:BEAT) Has A Pretty Healthy Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
- GlobeNewswire
BioTelemetry, Inc. Names Manish Wadhwa, M.D., F.H.R.S. Chief Medical Officer
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Manish Wadhwa, M.D., F.H.R.S. (Fellow of the Heart Rhythm Society), has been named Chief Medical Officer. Dr. Wadhwa will lead the company’s clinical strategy and operations, reporting to Joseph H. Capper, President and Chief Executive Officer. Dr. Wadhwa, co-founder of Geneva Health Solutions, joined BioTelemetry in March 2019 as part of the company’s acquisition of Geneva.
- Thomson Reuters StreetEvents
Edited Transcript of BEAT earnings conference call or presentation 30-Jul-19 9:00pm GMT
Q2 2019 BioTelemetry Inc Earnings Call
Motley FoolBioTelemetry Inc (BEAT) Q2 2019 Earnings Call Transcript
BEAT earnings call for the period ending July 30, 2019.
- Zacks
BioTelemetry (BEAT) Q2 Earnings and Revenues Beat Estimates
BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
BioTelemetry, Inc. Reports Second Quarter 2019 Financial Results
Exceeds Expectations Achieves Record Revenue and Adjusted EBITDA MALVERN, Pa., July 30, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology.
- GlobeNewswire
BioTelemetry, Inc. Acquires Sweden-based ADEA Medical AB and Expands International Service Offering
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner.
